CoChat
Sign Up
Cited by 2,575Multiple Myeloma Research and TreatmentsBone health and treatmentsChronic Lymphocytic Leukemia Research

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Open access
Singhal, Seema, Mehta, Jayesh, Desikan, Raman, Ayers, Dan, Roberson, Paula, Eddlemon, Paul, Munshi, Nikhil, Anaissie, Elias, Wilson, Carla, Dhodapkar, Madhav, Zeldis, Jerome, Siegel, David, Crowley, John, Barlogie, Bart·1999·New England Journal of Medicine
DOI 10.1056/nejm199911183412102
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Patients with myeloma who relapse after high-dose chemotherapy have few therapeutic options. Since increased bone marrow vascularity imparts a poor prognosis in myeloma, we evaluated the efficacy of thalidomide, which has antiangiogenic properties, in patients with refractory disease. METHODS: Eighty-four previously treated patients with refractory myeloma (76 with a relapse after high-dose chemotherapy) received oral thalidomide as a single agent for a median of 80 days (range, 2 to 465). The starting dose was 200 mg daily, and the dose was increased by 200 mg every two weeks until it reached 800 mg per day. Response was assessed on the basis of a reduction of the myeloma protein in serum or Bence Jones protein in urine that lasted for at least six weeks. RESULTS: The serum or urine levels of paraprotein were reduced by at least 90 percent in eight patients (two had a complete remission), at least 75 percent in six patients, at least 50 percent in seven patients, and at least 25 percent in six patients, for a total rate of response of 32 percent. Reductions in the paraprotein levels were apparent within two months in 78 percent of the patients with a response and were associated with decreased numbers of plasma cells in bone marrow and increased hemoglobin levels. The microvascular density of bone marrow did not change significantly in patients with a response. At least one third of the patients had mild or moderate constipation, weakness or fatigue, or somnolence. More severe adverse effects were infrequent (occurring in less than 10 percent of patients), and hematologic effects were rare. As of the most recent follow-up, 36 patients had died (30 with no response and 6 with a response). After 12 months of follow-up, Kaplan-Meier estimates of the mean (+/-SE) rates of event-free survival and overall survival for all patients were 22+/-5 percent and 58+/-5 percent, respectively. CONCLUSIONS: Thalidomide is active against advanced myeloma. It can induce marked and durable responses in some patients with multiple myeloma, including those who relapse after high-dose chemotherapy.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejm199911183412102

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 10

  1. Barlogie B, 1997, Clin Cancer Res, 3, 2605
  2. Singhal S, 1996, Blood, 88, 611a
  3. Munshi N, 1998, Blood, 92, 98a
  4. 10.2307/2281868 · DOI · Paper page
  5. Mantel N, 1966, Cancer Chemother Rep, 50, 163
  6. Figg WD, 1997, Proc Am Soc Clin Oncol, 16, 333a
  7. Fine HA, 1997, Proc Am Soc Clin Oncol, 16, 385a
  8. Long G, 1998, Proc Am Soc Clin Oncol, 17, 181a
  9. Eisen T, 1998, Proc Am Soc Clin Oncol, 17, 441a
  10. Nguyen M, 1997, Int J Oncol, 10, 965

Cited by

Sorted by citations

See all 2,575

Related

See all

Metadata

Authors
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeldis, J., Siegel, D., Crowley, J., & Barlogie, B.
Affiliations
  • University of South Carolina (US)
  • University of Arkansas for Medical Sciences (US)
  • Rockefeller University (US)
ORCID
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
1999-11-18
Volume
341
Issue
21
Pages
1565-1571
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejm199911183412102
OpenAlex
W2316160054
Cited by
2,575
References
35
Citations by year
2026: 27 · 2025: 41 · 2024: 48 · 2023: 48 · 2022: 69 · 2021: 73 · 2020: 62 · 2019: 67 · 2018: 56 · 2017: 62 · 2016: 69 · 2015: 75 · 2014: 76 · 2013: 102 · 2012: 89
FWCI
69.79
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (P01CA055819, CA-55819)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords
thalidomide, multiple myeloma, refractory multiple myeloma, anti-angiogenic therapy, Bence Jones protein, microvessel density, event-free survival, overall survival, adverse effects
MeSH terms
Bence Jones Protein, Bone Marrow, Bone Marrow Examination, Drug Administration Schedule, Female, Humans, Male, Microcirculation, Middle Aged, Multiple Myeloma, Myeloma Proteins, Recurrence, Remission Induction, Thalidomide, Multivariate Analysis, Survival Analysis, Disease Progression, Angiogenesis Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review